Tci Wealth Advisors, Inc. Incyte Corp Transaction History

Tci Wealth Advisors, Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 06, 2023	SELL	$67.18 - $84.11 $1,074 - $1,345	-16 Reduced 9.25%	157 $12,000
Q3 2022 Nov 08, 2022	BUY	$66.18 - $82.86 $463 - $580	7 Added 4.22%	173 $12,000
Q1 2022 Apr 29, 2022	BUY	$66.02 - $79.71 $1,320 - $1,594	20 Added 13.7%	166 $13,000
Q4 2021 Jan 24, 2022	BUY	$63.34 - $74.11 $9,247 - $10,820	146 New	146 $11,000
Q3 2021 Oct 29, 2021	SELL	$68.67 - $84.02 $2,472 - $3,024	-36 Closed	0 $0
Q2 2021 Aug 02, 2021	SELL	$79.87 - $87.53 $798 - $875	-10 Reduced 21.74%	36 $3,000
Q1 2021 Apr 29, 2021	BUY	$76.02 - $100.5 $3,496 - $4,623	46 New	46 $4,000
Q1 2020 Apr 14, 2020	SELL	$63.18 - $85.97 $315 - $429	-5 Closed	0 $0
Q4 2019 Jan 27, 2020	BUY	$73.04 - $95.72 $365 - $478	5 New	5 $0
Q4 2018 Jan 17, 2019	SELL	$58.5 - $69.94 $1,170 - $1,398	-20 Closed	0 $0
Q3 2018 Nov 02, 2018	BUY	$61.75 - $74.23 $1,235 - $1,484	20 New	20 $1,000
Q3 2017 Oct 24, 2017	SELL	$109.15 - $138.27 $545 - $691	-5 Closed	0 $0
Q2 2017 Aug 10, 2017	BUY	N/A	5	5 $1,000

652

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.1B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Tci Wealth Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Tci Wealth Advisors, Inc. with notifications on news.